Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2 Mutation”

124 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 124 results

Large-scale testing (Phase 3)Study completedNCT02184195
What this trial is testing

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Who this might be right for
Germline BRCA1/2 Mutations andMetastatic Adenocarcinoma of the Pancreas
AstraZeneca 154
Early research (Phase 1)Looking for participantsNCT06488378
What this trial is testing

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast CancerPALB2-Mutated Breast CarcinomaHER2-negative Breast Cancer+2 more
Dana-Farber Cancer Institute 20
Early research (Phase 1)Looking for participantsNCT06177171
What this trial is testing

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Who this might be right for
BRCA1 MutationBRCA2 MutationBRCA Mutation+3 more
Pamela Munster 18
Testing effectiveness (Phase 2)Looking for participantsNCT05485766
What this trial is testing

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more
Okayama University 23
Not applicableStudy completedNCT05750719
What this trial is testing

BRCA and NACT in TNBC Patients

Who this might be right for
Triple-Negative Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 136
Testing effectiveness (Phase 2)Ended earlyNCT02326844
What this trial is testing

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Who this might be right for
Ovarian Cancer
National Cancer Institute (NCI) 3
Early research (Phase 1)Study completedNCT03509636
What this trial is testing

Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd. 113
Not applicableStudy completedNCT03684733
What this trial is testing

Magnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast Cancer

Who this might be right for
BRCA1 MutationBRCA2 MutationMammography+1 more
Royal Marsden NHS Foundation Trust 28
Not applicableUnknownNCT04368442
What this trial is testing

Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation

Who this might be right for
Breast Cancer Metastatic
Samsung Medical Center 583
Not applicableActive Not RecruitingNCT02653105
What this trial is testing

Women at Risk of Breast Cancer and OLFM4

Who this might be right for
Hereditary Breast and Ovarian Cancer Syndrome
Institut Cancerologie de l'Ouest 150
Large-scale testing (Phase 3)Looking for participantsNCT06533384
What this trial is testing

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Who this might be right for
Triple-negative Breast Cancer
Guangdong Provincial People's Hospital 310
Early research (Phase 1)Study completedNCT01445418
What this trial is testing

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Who this might be right for
Breast CancerOvarian Cancer
National Cancer Institute (NCI) 103
Early research (Phase 1)Study completedNCT01339650
What this trial is testing

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian TubePrimary Peritoneal CancerSolid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian
AbbVie (prior sponsor, Abbott) 93
Not applicableLooking for participantsNCT02516540
What this trial is testing

Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers

Who this might be right for
Hereditary Breast and Ovarian Cancer
Technical University of Munich 600
Testing effectiveness (Phase 2)WithdrawnNCT05482074
What this trial is testing

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Who this might be right for
Recurrent Metastatic MelanomaCutaneous MelanomaMucosal Melanoma+1 more
Dana-Farber Cancer Institute
Not applicableUnknownNCT02670668
What this trial is testing

Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 100
Testing effectiveness (Phase 2)Study completedNCT01540565
What this trial is testing

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierOvarian Epithelial Tumor+3 more
National Cancer Institute (NCI) 52
Not applicableStudy completedNCT02151747
What this trial is testing

Testing BRCA 1/2 Mutation Using Next Generation Sequencing

Who this might be right for
Breast NeoplasmsBreast Cancer
Severance Hospital 12
Testing effectiveness (Phase 2)Study completedNCT04089189
What this trial is testing

Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer

Who this might be right for
Ovarian Cancer
Impact Therapeutics, Inc. 93
Early research (Phase 1)Looking for participantsNCT04890613
What this trial is testing

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Who this might be right for
Advanced Solid Tumor
Senhwa Biosciences, Inc. 52
Load More Results